2nd Annual MarketsandMarkets

ImmunoBio Series

14th - 15th October 2024

Freiburg im Breisgau, Germany

Introducing the 2nd Annual MarketsandMarkets ImmunoBio Series, a groundbreaking event uniting the realms of Biomarker and Immuno-Oncology, set to unfold on 14th - 15th October 2024 in Freiburg im Breisgau, Germany.

Dive deep into the convergence of biomarkers and immuno-oncology at our flagship conference, where industry pioneers, thought leaders, and experts converge to drive innovation in healthcare and biotechnology. This transformative event offers a dynamic platform for collaboration, knowledge exchange, and exploration of cutting-edge research and applications in personalized medicine and cancer treatment.

Esteemed keynote speakers will deliver groundbreaking insights into the latest developments and prospects of biomarker research and immuno-oncology, setting the stage for impactful discussions and networking opportunities. With over 40 speakers from leading pharma, biopharma, and biotech companies worldwide, attendees will gain invaluable insights into the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, and Cellular Therapy, shaping the future of immuno-oncology.

Experience immersive sessions, brainstorming panel discussions, and case studies that delve into the challenges and solutions in biomarker and immuno-oncology research and development. From oncology to non-oncology indications such as Alzheimer’s and Parkinson’s, discover the latest advancements revolutionizing personalized medicine pipelines.

Explore the frontier of healthcare innovation and collaboration at the 2nd Annual MarketsandMarkets ImmunoBio Series, where innovation meets collaboration to shape the future of healthcare and biotechnology. Join us for this transformative event and make a marked difference in patient outcomes.

WHAT TO EXPECT

  1. Preclinical and Translational Immuno-Oncology Developments
  2. Biomarker Discovery Techniques: Explore novel strategies, including genomics, proteomics, metabolomics, and bioinformatics, to identify cutting-edge biomarkers in oncology.
  3. Precision Medicine Tailoring: Understand the pivotal role of biomarkers in customizing immunotherapy for individual patients, enhancing efficacy, and minimizing side effects.
  4. Personalizing Cancer Treatment- Challenges and Opportunities
  5. Rigorous Biomarker Validation: Learn strategies and overcome challenges in validating biomarkers for clinical use, ensuring robust and reliable results.
  6. Bioinformatics and AI Analysis: Attend sessions on biomarker data analysis, employing machine learning and artificial intelligence approaches for comprehensive insights.
  7. Biomarker-Based Cancer Diagnostics Development: Gain insights into the development and commercialization of diagnostic tests and platforms based on biomarkers.
  8. Next Gen Antibodies and Targeted Therapies
  9. Immune Checkpoint Inhibitors and Combination Therapies
  10. Tumor Microenvironment and Cancer Biomarkers
  11. CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
  12. Cancer Vaccines and Cancer Microbiome
  13. Collaboration for Advancement: Explore sessions on fostering collaboration among academia, industry, and government agencies to drive biomarker research forward.

  1. Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer and immunology.
  2. Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
  3. Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
  4. Professional Development: Enhance your skills with workshops on cancer biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
  5. Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
  6. Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Engage in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

PRE-CLINICAL AND TRANSLATIONAL IO & IMMUNE CHECKPOINT BLOCKADES

Keynote Presentation - Reserved Slot for Platinum Sponsor

09:00 - 09:30

Innovative Preclinical Models for Investigating Tumor-Immune Interactions

09:30 - 10:00

Reserved Slot for Gold Sponsor

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Reserved Slot for Silver Sponsor

11:15 - 11:45

Translational approach in developing right IO therapy

11:45 - 12:15

ABX-001 (based on a Lymphocytic Choriomeningitis Virus), a First-in-class immunovirotherapy to fight solid cancers

Sarah-Kim Friedrich-Becker

Sarah-Kim Friedrich-Becker, Senior Principal Scientist, Abalos Therapeutics GmbH

12:15 - 12:45

Challenges and Opportunities in Validating Preclinical Models for Immuno-Oncology Drug Development

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

ADVANCEMENTS IN ANTIBODY AND CELL THERAPY

Solution Provider Presentation

14:15 - 14:45

Novel Bispecific PD-1 antibody therapeutic approach in solid tumours

14:45 - 15:15

Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies

15:15 - 15:45

Development of new generation DNA vaccines and novel mRNA-based Immunotherapy Vaccines

15:30 - 17:00

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 14:30

Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care

17:00 - 17:30

Closing Remarks from the Chairperson

17:00 - 17:00

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

ROLE OF CANCER BIOMARKERS IN PERSONALIZED MEDICINE

Keynote Presentation - Reserved for Platinum Sponsor

09:00 - 09:30

Unlocking the Potential of Multi-omics: Bridging Biomarkers and Personalized Therapies

09:30 - 10:00

Solution Provider Presentation-Reserved for Gold Sponsor

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Solution Provider Presentation-Reserved for Silver Sponsor

11:15 - 11:45

Assessing the Safety and Efficacy of ctDNA in Augmenting Immunotherapy Interventions

11:15 - 12:45

Functional biomarker assay development for cancer treatment

11:45 - 12:15

Advancements in Imaging Biomarkers for Cancer Diagnosis and Monitoring

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

OPTIMIZING PATIENT CARE AND THERAPEUTIC ASSESSMENT LEVERAGING IO MARKERS

Role of Biomarkers in Clinical Trials: Enhancing Patient Monitoring and Therapeutic Evaluation

14:15 - 14:45

Panel Discussion: Opportunities and Challenges in Biomarker Testing: Comparing Oncology and Non-Oncology Perspectives

14:45 - 15:15

Closing Remarks from the Chairperson

15:15 - 15:15

SPEAKERS

Eike Staub

Eike Staub

Head of Oncology Data Science, Merck Healthcare, Germany

Sarah-Kim Friedrich-Becker

Sarah-Kim Friedrich-Becker

Senior Principal Scientist, Abalos Therapeutics GmbH

Eric Halioua

Eric Halioua

President & Chief Executive Officer, PDC*line pharma SA

Rick Kamps

Rick Kamps

NGS Manager, Maastricht University

Louis Boon

Louis Boon

CSO and Board Member, JJP Biologics

Raj Mehta

Raj Mehta

Chief Executive Officer, Adendra Therapeutics Ltd

Despina Stefanoska

Despina Stefanoska

Business Development Manager, Biognosys

Elie Peillon

Elie Peillon

Associate Director Marketing, Veracyte

Christine Rothe

Christine Rothe

CDO, iOmx Therapeutics AG

Frank Jaschinski

Frank Jaschinski

CSO, Secarna Pharmaceuticals

Eytan Breman, Director

Eytan Breman, Director

Research & Development, Celyad Oncology

ENQUIRE NOW

SPONSORS

LOCATION

Venue

Freiburg im Breisgau, Germany

PAST EVENT GALLERY